Search research articles
Contact Us
Filters
Showing results (51-60 of 69) with videos related to
Page
of 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 10, 1999
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK)
A D Roth, R Herrmann, R Morant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1995
Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies
H Ludwig, A M Cohen, A Polliack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
J Bernhard, B Thürlimann, S F Schmitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2004
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial
A D Roth, R Maibach, N Fazio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
Y Seium, R Stupp, T Ruhstaller, et al.
British Journal of Cancer
|
November 28, 2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S Steinbild, K Mross, A Frost, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)
M M Borner, M Castiglione, M Bacchi, et al.
Cancer Chemotherapy and Pharmacology
|
September 6, 2000
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
N Pavlidis, S Aamdal, A Awada, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert, A Anthoney, W Fiedler, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 69) with videos related to
Sort By:
Page
of 7
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 1999
Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK)
J Bernhard, M Castiglione-Gertsch, S F Schmitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 10, 1999
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK)
A D Roth, R Herrmann, R Morant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1995
Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies
H Ludwig, A M Cohen, A Polliack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?
J Bernhard, B Thürlimann, S F Schmitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2004
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial
A D Roth, R Maibach, N Fazio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2005
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study
Y Seium, R Stupp, T Ruhstaller, et al.
British Journal of Cancer
|
November 28, 2007
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S Steinbild, K Mross, A Frost, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 8, 1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK)
M M Borner, M Castiglione, M Bacchi, et al.
Cancer Chemotherapy and Pharmacology
|
September 6, 2000
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)
N Pavlidis, S Aamdal, A Awada, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 26, 2001
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
B Coudert, A Anthoney, W Fiedler, et al.
Page
of 7